Katherine L. Nathanson

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag, Peter Hirth, James Tsai et al. · Nature · 2010 · 1.8K citations

Medicine, Oncology, Pharmacology +14

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Alexander C. Huang, Michael A. Postow, Robert J. Orlowski et al. · Nature · 2017 · 1.7K citations · Full text

Life Sciences, Immunology, Oncology +16

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

Sydney M. Shaffer, Margaret C. Dunagin, Stefan Torborg et al. · Nature · 2017 · 1.3K citations

Medicine, Cancer Biology, Oncology +16

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Jessie Villanueva, Adina Vultur, John Tayu Lee et al. · Cancer Cell · 2010 · 1.2K citations · Full text

Medicine, Cancer Biology, Oncology +13

Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk

Douglas F. Easton, Paul D.P. Pharoah, Antonis C. Antoniou et al. · New England Journal of Medicine · 2015 · 937 citations · Full text

Life Sciences, Genetics, Oncology +17